Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-06-21
2011-06-21
Vivlemore, Tracy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024500, C435S320100
Reexamination Certificate
active
07964575
ABSTRACT:
The present invention relates to an RNAi molecule suitable for reducing the expression of galectin-1 containing any of the sequences of SEQ ID NOs: 1-33, and preferably the sequences of SEQ ID NO: 2, 3, or 4, and to the use thereof as a medicament, or for the manufacture of a medicament for treating and/or for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma. The present invention also relates to compositions and methods for treating and for delaying the progression of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, for reducing the migration of tumor cells, preferably cells of glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, and/or for enhancing the efficacy of cancer therapies for the treatment of cancer, preferably glioma, pancreatic cancer, head and neck cancer, melanoma, non-small-cell lung cancer and non-Hodgkin's lymphoma, selected from the group comprising chemotherapy, radiation therapy, immunotherapy, and/or gene therapy.
REFERENCES:
patent: 2002/0173478 (2002-11-01), Gewirtz
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0153521 (2003-08-01), McSwiggen
patent: 2004/0018176 (2004-01-01), Tolentino et al.
patent: 2007/0178458 (2007-08-01), O'Brien et al.
patent: WO 0229031 (2002-04-01), None
patent: WO 03070912 (2003-08-01), None
patent: WO 2004/012817 (2004-02-01), None
Camby et al. Journal of Neuropathology and Experimental Neurology 2002, vol. 61, pp. 585-596.
Yamaoka et al. Journal of Neuroscience Research 2000, vol. 59, pp. 722-730.
Bass Nature 2001, vol. 411, pp. 428-429.
Vickers et al. Journal of Biological Chemistry 2003, vol. 278, pp. 7108-7118.
Camby, I. et al. (2005) Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern: Biochemical and Biophysical Research Communications 335:27-35.
Thakker, D. et al. (2004) “Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference” PNAS 101:17270-17275.
Schiffelers, R. et al. (2004) “Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle” Nuclleic Acids Research 32:1-10.
Aigner, A. (2006) “Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo” Journal of Biomedicine and Biotechnology 2006:1-15.
Bartlett, D. et al. (2006) “Insights into the kinetics if siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging” Nucleic Acids Research 34:322-333.
Filleur, S. et al. (2003) “SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth” Cancer Research 63:3919-3922.
Pai, S. et al. (2006) “Prospects of RNA interference therapy for cancer” Gene Therapy 13:464-477.
Rubinstein, N. et al. (2004) “Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege” Cancer Cell 5:241-251.
Rabinovich, G. (2005) “Galectin-I as a potential cancer target” British Journal of Cancer 92:1188-1192.
Camby Isabelle
Courtoy Pierre
Henriet Patrick
Kiss Robert
Lefranc Florence
Knobbe Martens Olson & Bear LLP
Universite Catholique de Louvain
Universite Libre De Bruxelles
Vivlemore Tracy
LandOfFree
Use of a galectin-1-targeted RNAi-based approach for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of a galectin-1-targeted RNAi-based approach for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of a galectin-1-targeted RNAi-based approach for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712042